Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
DMARDs for Treating JIA (2 of 2)
Methotrexate, a nonbiologic DMARD, is widely used and is considered by many to be part of standard care.
Although studies in pediatric populations have been performed, the evidence base regarding DMARDs for treatment of JIA is more limited compared with the wider experience and clinical evidence base in adult rheumatoid arthritis.
Long-term safety of the DMARDs used in children with JIA is not well understood.
Keywords: Juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | tumor necrosis factor-alpha | TNF-alpha | TNF-a
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.